Truqap (capivasertib) — United Healthcare
Breast Cancer
Initial criteria
- Diagnosis of breast cancer
- One of the following: Locally advanced OR Recurrent unresectable (local or regional) OR Metastatic
- Disease is hormone receptor (HR)-positive
- Disease is human epidermal growth factor receptor 2 (HER2)-negative
- Presence of one or more PIK3CA/AKT1/PTEN-alterations
- One of the following: Has progressed on at least one endocrine-based regimen in the metastatic setting (e.g., anastrozole, letrozole, exemestane, tamoxifen) OR Recurrence on or within 12 months of completing adjuvant therapy
- Used in combination with fulvestrant
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Truqap therapy
- Used in combination with fulvestrant
Approval duration
12 months